Magnesium sulphate subcutaneously injected protects against kainate-induced convulsions and neurodegeneration: in vivo study on the rat hippocampus.
Kainate, an agonist of a unique subclass of glutamate receptors (kainate receptor), was injected intracerebroventricularly in rats to induce convulsive reactions and hippocampal damage in order to model glutamate-mediated brain injury. Rats treated with magnesium sulfate (subcutaneously injected, up to 600 mg/kg) were found to be protected from kainate neurotoxicity depending on the dose and time of application. Results were largely consistent with those obtained previously by using quinolinate as an excitotoxic N-methyl-D-aspartate-receptor agonist. Magnesium is discussed as being a natural and relatively safe therapeutic in cases of glutamate-induced (hypoxic, ischemic, traumatic, or convulsive) disorders of the brain.
Wolf
G
G
Institute of Biology, Medical Academy of Magdeburg, F.R.G.
Fischer
S
S
Hass
P
P
Abicht
K
K
Keilhoff
G
G
D000818:Animals; D003292:Convulsants / Q000494:pharmacology; D006624:Hippocampus / Q000473:pathology*; D066298:In Vitro Techniques; D007279:Injections, Subcutaneous; D007608:Kainic Acid / Q000037:antagonists & inhibitors* / Q000633:toxicity; D008278:Magnesium Sulfate / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D009410:Nerve Degeneration / Q000187:drug effects*; D017378:Quinolinic Acid; D011805:Quinolinic Acids / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012640:Seizures / Q000139:chemically induced* / Q000473:pathology
D003292:Convulsants; D011805:Quinolinic Acids; D008278:Magnesium Sulfate; D017378:Quinolinic Acid; D007608:Kainic Acid